Dr Lal PathLabs announced a robust performance for the first quarter of FY27, with revenue growing by 19.1% year-on-year to reach ₹798 crore. This marks the highest quarterly growth rate in four years, driven by an 8.2% increase in patient volumes and a 10.7% rise in sample volumes. The company also highlighted strategic acquisitions and an interim dividend declaration.
Dr Lal PathLabs Reports Strong Q1 FY27 Performance
Dr Lal PathLabs Limited has reported a significant surge in its financial performance for the first quarter of the fiscal year 2027 (Q1 FY27), which ended on June 30, 2026. The company achieved a revenue of ₹798 crore, marking a substantial year-on-year growth of 19.1% compared to the same quarter in the previous fiscal year (Q1 FY26). This growth rate is the highest quarterly expansion recorded by the company in the last four years.
Key Growth Drivers Identified
The impressive revenue growth was primarily fueled by an increase in patient volumes, which rose by 8.2% to reach 8.2 million, and a 10.7% increase in sample volumes, totaling 25.9 million. The company emphasized that this performance is underpinned by its organic business strength, executed through three key pillars: Scientific Leadership, Enhanced Patient Experience, and Operational Excellence. Notable initiatives include the launch of 116 new tests, including four ‘first-in-India’ tests, and the introduction of an AI-powered patient bot on WhatsApp.
Financial Highlights and Profitability
EBITDA for the quarter stood at ₹247 crore, an increase of 28.7% from the previous year, with an EBITDA margin of 31.0%. Profit before tax (PBT) grew by 26.3% to ₹229 crore, resulting in a PBT margin of 28.7%. Profit after tax (PAT) saw a 27.2% increase, reaching ₹170 crore, with a PAT margin of 21.4%. Earnings per share (EPS) for Q1 FY27 was ₹10.1, an increase of 27.8% compared to the corresponding quarter last year.
Strategic Acquisitions and Dividend
The company also announced key strategic decisions, including the approval for the acquisition of an 80% equity stake in Sunshine Healthcare Limited in Ghana for a consideration not exceeding GHS 45.6 million. Additionally, a 30% equity stake in Neuome Technologies Private Limited was approved for a consideration not exceeding ₹3.5 crore, aimed at strengthening healthcare innovation. In line with its commitment to shareholder returns, the Board of Directors declared an interim dividend of 50% (₹5 per share).
Outlook and Future Plans
Dr Lal PathLabs expressed confidence in its outlook, anticipating sustainable and profitable growth. The company plans to reinvest in the business for future growth and will provide further clarity on guidance after the second quarter. The focus remains on scaling existing operations, deepening market reach, and exploring new markets, including rural areas.
Source: BSE
